In this 12-week , multicenter , placebo-controlled trial , 268 subjects > or = 12 years of age with inhaled corticosteroid-dependent asthma and baseline forced expiratory volume in 1 second ( FEV ( 1 ) ) between 50 % and 85 % of predicted were randomized to receive treatment with MF-DPI 400 mug once daily in the evening , MF-DPI 200 mug twice daily , or placebo .
